User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- N30 Pharmaceuticals company
- Hello Do you have information regarding the progress of research performed on 2 molecules ((n91115 et n6022) from N30 Pharmaceuticals company? Can we have hope that this type of drug could emerge soon? Do you think that these molecules and the miglustat, based on their mechanism of action, ...
- 26.05.2014
- Amlexanox
- Dear expert team, I got aware of the following publications: http://www.ncbi.nlm.nih.gov/m/pubmed/22938201/ and http://www.google.com/patents/EP2437741A1?cl=en I would like to know if there is any data yet concerning the correction of CF nonsense mutations? Respectively, if there are any ...
- 12.05.2014
- Nitric oxide therapy
- Hello, are there already any news concerning the above mentioned therapeutic trial? Thanks.
- 29.04.2014
- Research on delF508 mutation
- Hello It’s not the first time I ask you a question, and first of all I would really thank you for the help, the information and sometimes the comfort that you bring us through this website. I don’t want to abuse your precious time but could you resume in a few lines the research which is ...
- 28.04.2014
- Meveol®
- Hello I have just read: « A new treatment against cystic fibrosis could emerge by 2016. This is a project supported by Bpifrance (bank financing and investment) who just released € 10 million for a new medical program called Alipex. Of the three companies involved in research: Alaxia, a ...
- 15.04.2014
- Living in Athens with CF Recommended ?
- I have an 11 year old daughter with CF and we live in Abu Dhabi, UAE, but we may come to live in Athens, I am worried about the air pollution, we will be living in the hills outside Athens. Also Gala has just started to take Ivacaftor as she has the G551 mutation, is this going to be available ...
- 24.03.2014
- Kalydeco® off-label
- Dear expert team, my son has the following CFTR mutations: 1717-1G>A (class 1) und die mutation S549R (gating/connection, class 2 oder 3) Kaleydeco ® has indeed at the moment only market authorization for the class 3 mutation G551D. However, tests with other mutations have been done. There it ...
- 12.02.2014
- MIGLUSTAT
- Hello Do you have any news regarding research about MIGLUSTAT? Thank you.
- 03.02.2014
- Therapy of the protein
- Hello, We have learned in September by the "INSERM" (french national institute for health and medical research), about the discovery of 2 molecules acting on deltaF508 CFTR protein. What is the difference between theses 2 molecules and Vertex’s molecules (Ivacaftor® and Lumacaftor®) that are ...
- 08.01.2014
- POTENTIATOR / GALAPAGOS
- Hello An article published on 12/16/13 indicates that the biotechnology company Galapagos has a new drug candidate (potentiator) which will be tested in clinical trials. How much credit can you give to this notification? Have you more information? Thanks
- 08.01.2014
